TARS - Company ID 0001819790
Tarsus Pharmaceuticals, Inc. trades as TARS and has a market capitalization of $2.74 B, making it the #1912 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $451.36M, up 146.7% from the prior year and net income of -$66.00M. This page tracks Tarsus Pharmaceuticals, Inc. through 614 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -24.2% to -14.6% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
Tarsus to Participate in Upcoming Investor Conferences | Tarsus Pharmaceuticals
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans | Tarsus Pharmaceuticals
Tarsus to Participate in Upcoming Investor Conferences | Tarsus Pharmaceuticals
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements | Tarsus Pharmaceuticals
Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission
The largest companies sharing Tarsus Pharmaceuticals, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of $2.74 B as of 2026-07-09, ranking #1912 among US-listed companies.
Tarsus Pharmaceuticals, Inc. reported revenue of $451.36M for fiscal year 2025, an increase of 146.7% year over year.
In its latest fiscal year Tarsus Pharmaceuticals, Inc. reported a net loss of $66.00M.